Cell Transplantation最新文献

{"title":"Research landscapes and knowledge structure of cardiac xenotransplantation: A bibliometric analysis.","authors":"Shangxuan Li, Guanzheng Cui, Ziqiang Dai, Zhipeng Ren, Jiahong Wang, Xianzhi Wang, Gen Zhang, Dongsheng He, Huan Wang, Xin Li, Dianyuan Li","doi":"10.1177/09636897261431049","DOIUrl":"10.1177/09636897261431049","url":null,"abstract":"<p><p>Cardiac xenotransplantation is advancing rapidly from basic research to early clinical use, but its research landscape has not been comprehensively mapped. We conducted a bibliometric and science-mapping analysis of English-language articles and reviews in the Web of Science Core Collection (1964-2025). Using VOSviewer, CiteSpace, and Bibliometrix, we assessed publication growth, collaboration networks, citation impact, and topic trends. The field has grown steadily and has accelerated in recent years in parallel with key clinical developments. Collaboration is strongest among institutions in the United States, Europe, and East Asia, and a small number of authors and centers contribute a large share of publications. Most studies are published in specialty transplantation journals, whereas major breakthroughs often appear in general medical journals. Research topics continue to focus on rejection and complement biology, while newer work highlights gene-edited donors, biosafety, clinical trial readiness, and pig-to-human models. Overall, the field appears to be maturing toward clinical implementation, and these findings can help guide research priorities, funding decisions, and policy planning.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261431049"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13009822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147484899","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HHV-7 encephalitis following allogeneic hematopoietic stem cell transplantation: A case report and literature review.","authors":"Yilei Ma, Leqing Cao, Fengrong Wang, Hui Sun, Xiaodong Mo","doi":"10.1177/09636897261476835","DOIUrl":"10.1177/09636897261476835","url":null,"abstract":"<p><p>Human herpesvirus 7 (HHV-7) encephalitis commonly occurs in immunocompromised individuals and has a poor prognosis. We here reported 3 cases of HHV-7 encephalitis following allogeneic hematopoietic stem cell transplantation (allo-HSCT) with typical neurological symptoms, including altered consciousness and epileptic seizures, and conducted a systematic review of the literature to identify clinical characteristics and management strategies in these patients. Cerebrospinal fluid next-generation sequencing (NGS) was the key evidence that led to their diagnosis. Foscarnet and cidofovir appeared effective, particularly with at least four weeks of treatment. All three patients showed at least partial improvement in neurological symptoms. Furthermore, a systematic search was conducted in PubMed, Google Scholar, and Web of Science to identify related cases. Clinical presentation, diagnostic findings, treatment strategies, and outcomes were analyzed. A total of 10 publications were included, together with our 3 cases, comprising 7 cases of HSCT recipients for detailed analysis. Our study suggested that early recognition and prompt antiviral therapy are critical for improving prognosis. Further exploration is needed regarding risk factors and treatment strategies.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261476835"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13443236/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148677224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative analysis of the bio-safety of HuMSCs and HuMenSCs in the nude mice and their impacts on reproductive organs' histological morphology.","authors":"Zhaoyi Li, Wanxian Huang, Tai Ip Chan, Gang Xiao, Yibing Han, Yi Zhun Zhu","doi":"10.1177/09636897261446726","DOIUrl":"10.1177/09636897261446726","url":null,"abstract":"<p><p>The tumorigenesis and long-term bio-function of the implanted mesenchymal stromal cells (MSCs) were needed before clinical applications. We herein observed 7 months and investigated the viable tumors formation, the survival rate, the distribution of the injected cells in different reproductive organs after intravenous (IV) injection of the human menstrual blood-derived MSCs (LXT- and CDH-huMenSCs), and the human umbilical MSCs (huMSCs). The survival rate was not different among the huMenSCs, the huMSCs, and the negative control (IV injection of PBS) group. The longevities of the mice died within the observation period of the LXT and the huMSCs groups were significantly longer than that in the other groups; the positive control (IV injection of LLC (Lewis lung carcinoma cells)) group had the shortest longevity. The number of visible tumors in the huMenSCs, huMSCs, and the negative control group was lower than that in the positive control group. Human-sourced DNA was only detected in the ovaries of the huMSCs-injected mice. The histological morphology of the CDH- group had more normal follicles than that in other groups; the CDH- and the huMSCs group had more atretic follicles than that in other groups. In the huMenSCs and the huMSCs groups, the testis seminiferous tubules were fuller and more orderly arranged than the negative control group. The endometrial thickness of the LXT- group was thicker than that of the huMSCs- and the negative control groups, whereas the number of uterine glands was similar among all groups. The results suggested that IV administrations of xenogeneic huMenSCs and huMSCs in nude mice did not cause tumor formation. The injected huMenSCs from different donors functioned differentially on the mice's life-span, endometrial thickness, and the number of follicles.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261446726"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13222443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148101182","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Host immune determinants of stromal vascular fraction graft survival: Toward a concept of SVF therapy resistance - A systematic narrative review.","authors":"Caroline Nonnarath, Nicolas Serratrice","doi":"10.1177/09636897261469003","DOIUrl":"10.1177/09636897261469003","url":null,"abstract":"<p><p>Stromal vascular fraction (SVF)-based therapies and autologous fat grafting have emerged as promising regenerative strategies due to their pro-angiogenic, immunomodulatory, and trophic properties. However, despite encouraging preclinical and clinical findings, therapeutic outcomes remain highly heterogeneous, with marked variability in graft retention and functional efficacy between patients. Increasing evidence suggests that this variability cannot be explained solely by procedural factors or cellular composition, but may also depend on host-related immune and microenvironmental determinants. This review explores the biological mechanisms governing SVF engraftment and introduces the emerging concept of \"SVF therapy resistance,\" defined as the failure of autologous regenerative therapies resulting from maladaptive interactions between transplanted stromal cells and the host tissue environment. Particular attention is given to sterile inflammation, innate immune activation, and early graft-host interactions. Following transplantation, tissue injury and ischemia induce the release of danger-associated molecular patterns (DAMPs), triggering neutrophil recruitment, macrophage activation, complement signaling, and inflammatory remodeling. While controlled inflammatory responses may support tissue repair and angiogenesis, excessive neutrophil activation, neutrophil extracellular trap (NET) formation, persistent pro-inflammatory macrophage polarization, and impaired vascular adaptation may compromise graft survival and regenerative efficacy. The review further discusses how SVF processing, inflammatory priming, stromal cell heterogeneity, and donor-related factors-including obesity, aging, metabolic dysfunction, and chronic inflammation-may influence therapeutic responsiveness. Emerging evidence from mesenchymal stromal cell biology suggests that stromal cells are highly sensitive to inflammatory licensing and microenvironmental cues. Candidate biomarkers and immune profiling strategies capable of identifying responders and non-responders to SVF-based therapies are also reviewed. Finally, these mechanisms are discussed in spinal cord injury, a condition characterized by chronic inflammation and vascular dysfunction. Overall, this review proposes a translational framework linking innate immunity, sterile inflammation, angiogenesis, and stromal cell heterogeneity to the variability of SVF therapy outcomes, highlighting the need for personalized regenerative medicine approaches.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261469003"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13369406/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148435221","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Optimizing dose and delivery route in mesenchymal stromal cells (MSCs)-based therapy: A systematic review of their implications for clinical efficacy.","authors":"Cynthia Retna Sartika, Rima Haifa, Angliana Chouw, Atikah Anwar Hasibuan, Karina Kalasuba, Lestari Mahardika Urbaningrum","doi":"10.1177/09636897261457229","DOIUrl":"10.1177/09636897261457229","url":null,"abstract":"<p><p>Mesenchymal stromal cell (MSC)-based therapies have demonstrated broad therapeutic potential across inflammatory, degenerative, and neurological disorders; however, clinical outcomes remain highly variable, largely due to heterogeneity in cell source, dosing strategies, routes of administration, treatment timing, and patient-specific factors. This review evaluates how MSC dose and delivery route influence clinical efficacy and safety, and whether specific administration routes require tailored dosing strategies. A systematic literature search of PubMed, Scopus, Web of Science, and the Cochrane Library (2015-2025) identified 29 eligible clinical trials employing intravenous (n = 13), intrathecal (n = 10), intramuscular (n = 4), intranasal (n = 1), and multi-route (n = 1) administration, with doses ranging from 2 × 10⁵ cells/kg body weight to fixed doses exceeding 1 × 10⁸ cells. Intravenous delivery was predominantly used for systemic indications but was limited by pulmonary first-pass sequestration, whereas intrathecal and intranasal routes enhanced central nervous system targeting and intramuscular administration supported prolonged local persistence and paracrine activity. Although MSC therapy was generally well tolerated across studies, substantial outcome variability underscores the need for harmonized frameworks for dose selection, route optimization, and manufacturing consistency. This review highlights critical gaps in dose-route optimization and supports the development of standardized clinical guidelines and advanced strategies, including MSC priming and engineering, to improve therapeutic predictability and translational success.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261457229"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13263514/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148223493","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"3D bioprinting and mesenchymal stem cells: A bibliometric analysis of emerging trends and advancements.","authors":"Yi-Cheng Li, Bo Shao, Kui Ye, Xu Liu, Hong-da Wang, Cheng-Lu Sun, Yi-Yi Xiao, Hao Wang","doi":"10.1177/09636897251410650","DOIUrl":"10.1177/09636897251410650","url":null,"abstract":"<p><p>Recent years have witnessed rapid advancements in 3D bioprinting and the widespread application of mesenchymal stem cells (MSCs) across various medical disciplines. The synergistic integration of 3D bioprinting and MSCs has opened innovative avenues for tissue engineering and regenerative medicine, particularly in bone tissue repair and regeneration. However, the progress of 3D bioprinting in the field of MSCs research still requires further exploration, and there remains a scarcity of related bibliometric analyses in this domain. With the aim of addressing this existing gap, this research systematically searched the Web of Science Core Collection for publications spanning from January 2003 to October 2025. It employed CiteSpace for cluster and evolution analysis, VOSviewer for collaboration network and keyword co-occurrence analysis, and the R package \"bibliometrix\" for statistical evaluation of bibliometric indicators. This bibliometric analysis focused on tissue engineering research integrating 3D bioprinting with MSCs, encompassing 1,846 original articles. These articles were authored by 10,276 researchers from 2,024 institutions across 69 countries and published in 342 academic journals. From 2014 to 2023, the number of annual publications exhibited a fluctuating yet rapid upward trend. China and the United States emerged as the most influential countries, with China experiencing a particularly substantial increase in research output-though international collaborations among institutions and authors remained limited. Wu C.T. and Bose S. stood out as key contributors to this field, while journals such as <i>Biomaterials</i> and <i>Biofabrication</i> have significantly advanced the discipline. High-frequency keywords including \"3D printing\" and \"tissue engineering\" reflected the core research directions, whereas emerging terms such as \"MSC-EVs\" and \"nanocomposites\" indicated current frontiers; in addition, \"bioink,\" \"3D scaffold,\" \"osteogenesis,\" and \"angiogenesis\" represented areas gaining growing research attention. Overall, this bibliometric study provides a thorough overview of the research tendencies and developments related to 3D bioprinting in the MSC field.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251410650"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812190/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988417","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Temporal dynamics of mesenchymal stem cell administration influence immune modulation in a 4T1 breast cancer model.","authors":"Dragana Papic, Dragica Pavlovic, Danijela Niciforovic, Vladimir Jurisic, Vladislav Volarevic","doi":"10.1177/09636897251414744","DOIUrl":"10.1177/09636897251414744","url":null,"abstract":"<p><p>Mesenchymal stem cells (MSCs) are recognized for their capacity to modulate immune responses, including those directed against tumors. In this study, we investigated the temporal effects of MSCs administration on anti-tumor immunity in a murine 4T1 breast cancer model. BALB/c mice were intraperitoneally injected with MSCs either 24 h (MSC1d) or 14 days (MSC14d) after orthotopic implantation of 4T1 mammary carcinoma cells. Early MSC administration (MSC1d) exhibited changes in immune cell phenotypes consistent with enhanced antitumor potential, including increased activity of natural killer (NK) cells, dendritic cells (DCs), macrophages, and T lymphocytes. These immunological changes correlated with reduced tumor growth and prolonged survival. Mice in the MSC1d group exhibited elevated serum levels of pro-inflammatory and anti-tumor cytokines (TNF-α, IFN-γ, IL-6, and IL-17), alongside decreased concentrations of immunosuppressive cytokines (TGF-β and IL-10). Tumor tissue analysis revealed increased infiltration of NK cells expressing markers associated with antitumor activity (IFN-γ-producing CD178⁺), CD80⁺/CD86⁺/I-A⁺ TNF-α-producing DCs, Th1-type CD4⁺ T cells, and Granzyme B-expressing CD8⁺ cytotoxic T lymphocytes (CTLs). Additionally, spleens of MSC1d-treated mice displayed significantly elevated populations of CD11c⁺ DCs, TNF-α/IFN-γ-secreting NK cells, CD4⁺ Th1 and Th17 cells, and CD8⁺ CTLs expressing markers associated with cytotoxic function (TNF-α, IFN-γ, and IL-17). Conversely, late MSCs administration (MSC14d) was associated with immunosuppression. Tumors from MSC14d-treated mice showed a decreased presence of IFN-γ⁺ and IL-17⁺ NK1.1⁺ cells, F4/80⁺ macrophages, IL-12⁺ DCs, and cytotoxic T cells. Spleens from these mice revealed a significant expansion of regulatory T cell (Treg)-like populations, including CD25⁻, FoxP3⁻, CD25⁺FoxP3⁻ cells, and TGF-β/IL-10-producing CD3⁺ and CD4⁺ T cells. Furthermore, serum levels of immunosuppressive mediators TGF-β and vascular endothelial growth factor (VEGF) were significantly elevated in the MSC14d group. Collectively, these findings demonstrate that the immunomodulatory effects of MSCs on breast cancer are highly dependent on the timing of their administration. Mesenchymal stem cells delivered during early tumor development enhance phenotypes consistent with antitumor potential and suppress tumor progression, whereas administration during later stages promotes immune evasion and tumor growth.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251414744"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12852577/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146059776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Cellular replacement therapy for diabetes.","authors":"Naoaki Sakata, Gumpei Yoshimatsu, Shohta Kodama","doi":"10.1177/09636897251392313","DOIUrl":"10.1177/09636897251392313","url":null,"abstract":"<p><p>Diabetes mellitus (DM) is a metabolic disorder with chronic hyperglycemia due to insulin deficiency and/or impaired insulin action. DM is a common disease, but it often threatens a patient's quality of life. Cellular replacement therapy using insulin-producing cells is a promising therapy for severe DM because of the proper provision of internal insulin according to a change in blood glucose concentrations. This Special Collection, \"Cellular Replacement Therapy for Diabetes,\" was planned to appeal the current status and present novel translational trials of this therapy. Ten specialists presented their research, which attempted to overcome three limitations of the current cellular replacement therapy, including the regulation of immunity, limited donor supplies, and establishment of a preferable transplant site for cellular replacement therapy. Regarding regulation of immunity, potential of mesenchymal stem cells and immunomodulatory splenocytes is clarified. Regarding alternative donors, the current status of porcine islet xenotransplantation and therapy using multipotent stem cell-derived cells is introduced. And regarding transplant site, possibility of liver surface and subcutaneous tissue is elucidated.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251392313"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12833175/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146028576","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prognostic impact of clinico-genetic characteristics and donor types in <i>NPM1</i>-mutated AML undergoing allogeneic hematopoietic stem cell transplantation.","authors":"Xiaolin Yuan, Yibo Wu, Tingting Yang, Panpan Zhu, Xiaoyu Lai, Lizhen Liu, Luxin Yang, Jimin Shi, Jian Yu, Yanmin Zhao, Weiyan Zheng, Jie Sun, Wenjun Wu, Yi Zhao, Zhen Cai, He Huang, Shanshan Pei, Yi Luo","doi":"10.1177/09636897251414205","DOIUrl":"10.1177/09636897251414205","url":null,"abstract":"<p><p><i>NPM1</i>-mutated acute myeloid leukemia (AML) is a distinct entity with specific biological and clinicopathological features. Prognosis varies depending on the associated mutations and clinical characteristics. This study evaluated the prognostic factors of <i>NPM1</i>-mutated AML in patients who underwent allogeneic hematopoietic stem cell transplantation (allo-HSCT). We enrolled 139 patients with <i>NPM1</i>-mutated AML who underwent allo-HSCT. The median age at allo-HSCT was 47 years with a median follow-up of 1,134 days. The 3-year cumulative incidence of relapse (CIR), leukemia-free survival (LFS), and overall survival (OS) rates were 15.1%, 78.4%, and 78.0%, respectively. <i>FLT3-ITD</i> mutations showed higher CIR (22.6% vs 5.3%, <i>P</i> = 0.006), lower LFS (70.9% vs 88.1%, <i>P</i> = 0.019), and reduced OS (70.8% vs 87.5%, <i>P</i> = 0.036). <i>FLT3-ITD</i> and DTA mutations indicated adverse prognosis, while <i>IDH1/2</i> mutations showed improved outcomes. Matched sibling donor (MSD) allo-HSCT patients had higher CIR and lower LFS and OS than unrelated donor (URD) or haploidentical-related donor (HRD) recipients. Pre-HSCT MRD status affected the outcomes, with MRD+ and nCR patients showing worse outcomes. Multivariable analysis identified <i>FLT3-ITD</i>, MSD, and pre-MRD status as significant predictors. In conclusion, <i>FLT3-ITD</i> and DTA mutations are associated with an adverse prognosis, whereas HRD or URD transplants may offer better outcomes than MSD allo-HSCT.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897251414205"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12901938/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146178105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Total marrow irradiation-based conditioning for allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies: A multicenter real-world study.","authors":"Yi Zhang, Ran Zhang, Xiena Cao, Yang Yang, Weiwei Jin, Yu Chen, Liling Zhang, Hui Zeng, Ruowen Wei, Ao Zhang, Hongru Chen, Li Wang, Yang Cao, Weijie Cao, Linghui Xia, Wei Shi","doi":"10.1177/09636897261440297","DOIUrl":"10.1177/09636897261440297","url":null,"abstract":"<p><p>Currently, there is very limited large-scale real-world data on the use of total marrow irradiation (TMI) as conditioning for allogeneic hematopoietic stem cell transplantation (allo-HSCT). The primary objective of this study was to evaluate the real-world feasibility, efficacy, and safety of TMI-based conditioning in a large multicenter cohort. We retrospectively included consecutive patients undergoing allo-HSCT with TMI-based conditioning across four Chinese centers (2017-2024). The primary endpoint was overall survival (OS); secondary endpoints included disease-free survival (DFS), graft-versus-host disease-free/relapse-free survival (GRFS), nonrelapse mortality (NRM), graft-versus-host disease (GVHD), and safety. Among 205 patients, acute lymphoblastic leukemia (ALL) was the predominant diagnosis (81.5%). With a median follow-up of 19.3 months among survivors, 2-year OS, DFS, and GRFS were 71.7%, 60.0%, and 37.8%, respectively. One-year cumulative incidences of relapse and NRM were 20.2% and 13.8%. Day-100 grade II-IV acute GVHD occurred in 32.9%, and 1-year moderate-to-severe chronic GVHD in 19.1%. In multivariable analyses, acute myeloid leukemia (AML) diagnosis, haploidentical donor, and Eastern Cooperative Oncology Group (ECOG) performance status >1 were associated with inferior outcomes. Exploratory dose-stratified analyses were performed. Severe toxicities within 100 days were infrequent, predominantly infections (21.46%). In this large multicenter cohort, TMI-based conditioning demonstrated real-world feasibility with encouraging survival and manageable safety outcomes.</p>","PeriodicalId":9721,"journal":{"name":"Cell Transplantation","volume":"35 ","pages":"9636897261440297"},"PeriodicalIF":3.7,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13100420/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147697589","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}